Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.59 |
| ▸ | LTA4H | P09960 | 2/20 | 0.59 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.58 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | APP | P05067 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23969990 | 0.95 | LSS (0.56) | HRH3LTA4HKEAP1NFE2L2KDM4E | |
| SCHEMBL23970012 | 0.86 | LSS (0.68) | HRH3KDM4EALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL4272107 | 0.81 | CYP2D6 (0.61) | HRH3LTA4HKDM4ECYP1A2CYP2D6 | |
| SCHEMBL13165626 | 0.80 | HRH3 (0.54) | HRH3LTA4HKEAP1NFE2L2KDM4E | |
| SCHEMBL11877542 | 0.80 | LTA4H (0.67) | HRH3LTA4HKEAP1NFE2L2KDM4E | |
| SCHEMBL24955606 | 0.79 | CHRNB2 (0.61) | LTA4HKEAP1NFE2L2KDM4EALDH1A1 | |
| SCHEMBL14368317 | 0.79 | HRH3 (0.55) | HRH3LTA4HKEAP1NFE2L2KDM4E | |
| SCHEMBL14452030 | 0.78 | HRH3 (0.66) | HRH3LTA4HKEAP1NFE2L2KDM4E | |
| SCHEMBL2095905 | 0.78 | APP (0.57) | LTA4HAPP | |
| SCHEMBL14922323 | 0.78 | HRH3 (0.66) | HRH3LTA4HKEAP1NFE2L2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022119756-A9 | COMPOSITIONS AND METHODS FOR INHIBITING M PRO PROTEASE ACTIVITY AND FOR PREVENTING AND TREATING SARS-COV-2 INFECTION | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2023-04-27 | — | — | WO | disclosed |
| EP-4011882-A1 | 4-SUBSTITUTED AMINOISOQUINOLINE DERIVATIVES | Purdue Research Foundation (US) | 2022-06-15 | — | — | EP | disclosed |
| US-11001559-B2 | 4-substituted aminoisoquinoline derivatives | PURDUE RESEARCH FOUNDATION (US) | 2021-05-11 | — | — | US | disclosed |
| US-20190177278-A1 | 4-SUBSTITUTED AMINOISOQUINOLINE DERIVATIVES | PURDUE RESEARCH FOUNDATION (US) | 2019-06-13 | — | — | US | disclosed |
| US-20110098296-A1 | Thiazole And Oxazole Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177278-A1 | 4-SUBSTITUTED AMINOISOQUINOLINE DERIVATIVES | MCL1, ABL1, FLT3 | HRH3 1421/4885LTA4H 3613/4885KEAP1 941/4885 |
| US-20110098296-A1 | Thiazole And Oxazole Kinase Inhibitors | PDXK, MAP3K1, MAP4K2 | HRH3 3230/4885LTA4H 3394/4885KEAP1 900/4885 |
| US-11001559-B2 | 4-substituted aminoisoquinoline derivatives | MCL1, ABL1, FLT3 | HRH3 1421/4885LTA4H 3613/4885KEAP1 941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.